Aetna got out of the ACA marketplace business in 2018. Now CVS Health, which completed its acquisition of the insurance company in late 2018, is hopping back in and will brand the policies as a “CVS Health-Aetna” product for the first time.
Aetna got out of the ACA marketplace business in 2018. Now CVS Health, which completed its acquisition of the insurance company in late 2018, is hopping back in and will brand the policies as a “CVS Health-Aetna” product for the first time, Karen S. Lynch, the company’s new president and CEO, said during an earnings call last month.
“As the ACA has evolved, there is evidence of market stabilization and remedies to earlier structural issues,” Lynch said during the Feb. 16 call. “It is now time for us to participate in these markets.”
Lynch said CVS Health would start selling coverage that would start in January 2022, but she shared no details about how many markets the company might sell CVS Health-Aetna coverage in or which ones.
She noted that the ACA marketplace market was a big one of 10 to 15 million people. After a Supreme Court ruling favoring insurers, CVS Health was among those that received a hefty ACA risk corridor payment. The company booked a $307 million risk corridor payment in 2020.
The ACA marketplace plans may also benefit from President Joe Biden’s proposal to increase the subsidies that lower premium costs for Americans who buy ACA marketplace coverage.
CVS Health is a huge ($286.7 billion revenues last year), publicly traded company, but like many of its competitors, it has seen the proportion of its government business (Medicare Advantage, Medicaid) grow relative to its commercial business.
For example, the number of people in its insured commercial plans decreased from 3,591,000 in 2019 to 3,258,000 in 2020, a difference of 333,000, or 9.3%, according to year-end results posted at the time of the earnings call. Meanwhile, the number of people in its Medicare Advantage plans increased from 2,321,000 in 2019 to 2,705,000 in 2020, an increase of 384,000, or 16.5%.
GLP-1s Are Flipping the Script, Says Doug Long | 2024 Asembia
May 1st 2024The growth in spending on the glucagon-like peptide 1 (GLP-1) agonists is a “mega tsunami,” said Doug Long, MBA, vice president industry relations for IQVIA. The script that specialty drugs are the main drivers of U.S. drug expenditures may need some revision.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
Study Reveals Patients Benefit More with Female Doctors — More Particularly Female Patients
April 30th 2024Understanding how physician sex contributes to these disparities is crucial as evidence on the impact of physician sex on clinical outcomes remains limited, especially around patient sex.
Read More